Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Essential Role of ß3 PSI Domain in Integrin Receptor Assembly, Expression & Function
FY 2022-23
Summary
Cardiovascular diseases such as heart attack and stroke are the leading causes of morbidity and mortality worldwide. While current antithrombotic therapies have reduced mortality, serious adverse side effects remain for patients. Platelets are small, anucleate white blood cells that are key mediators of hemostasis through adherence at sites of vessel injury for blood clot formation (thrombosis). ?IIb?3 integrin receptor is highly expressed on platelets and has an integral role in platelet tethering. While traditional anti-thrombotic therapies target the main binding domain of ?IIb?3, such pharmaceuticals introduce bleeding risk to patients. Located on the ? subunit of all integrin family members is the highly conserved Plexin-Semaphorin-Integrin (PSI) domain. Our lab recently established PSI domain thiol isomerase activity (ability to shuffle disulfide bonds). Interestingly, anti-PSI antibodies have demonstrated superior anti-thrombotic therapeutic potential. We hypothesize ?3 integrin PSI domain thiol isomerase activity is a key regulator of integrin expression, and thus a novel target for anti-thrombotic therapy. Through examination of translated HEK-293T cells via flow cytometry and Biomembrane Force probing, mutations of PSI will elucidate PSI role for ?IIb?3 function. Additionally, the use of thiol isomerase assays will examine PSI mutations impact on disulfide bond formation. This work will further characterize novel anti-PSI domain antibodies as an anti-thrombotic therapeutic. Due to the high conservation of the PSI domain across mammalian cells for hundreds of millions of years, our findings are not only applicable to thrombosis & hemostasis but provide insight into basic science regarding the vast integrin family and its mechanism of activation and function.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486335
Name
Hoard Brock K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Essential Role of ß3 PSI Domain in Integrin Receptor Assembly, Expression & Function
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alphaiib Betaiii; Hemostasis; Integrin; Platelets; Psi Domain; Thiol Isomerase Activity; Thrombosis
Abstract
Cardiovascular diseases such as heart attack and stroke are the leading causes of morbidity and mortality worldwide. While current antithrombotic therapies have reduced mortality, serious adverse side effects remain for patients. Platelets are small, anucleate white blood cells that are key mediators of hemostasis through adherence at sites of vessel injury for blood clot formation (thrombosis). ?IIb?3 integrin receptor is highly expressed on platelets and has an integral role in platelet tethering. While traditional anti-thrombotic therapies target the main binding domain of ?IIb?3, such pharmaceuticals introduce bleeding risk to patients. Located on the ? subunit of all integrin family members is the highly conserved Plexin-Semaphorin-Integrin (PSI) domain. Our lab recently established PSI domain thiol isomerase activity (ability to shuffle disulfide bonds). Interestingly, anti-PSI antibodies have demonstrated superior anti-thrombotic therapeutic potential. We hypothesize ?3 integrin PSI domain thiol isomerase activity is a key regulator of integrin expression, and thus a novel target for anti-thrombotic therapy. Through examination of translated HEK-293T cells via flow cytometry and Biomembrane Force probing, mutations of PSI will elucidate PSI role for ?IIb?3 function. Additionally, the use of thiol isomerase assays will examine PSI mutations impact on disulfide bond formation. This work will further characterize novel anti-PSI domain antibodies as an anti-thrombotic therapeutic. Due to the high conservation of the PSI domain across mammalian cells for hundreds of millions of years, our findings are not only applicable to thrombosis & hemostasis but provide insight into basic science regarding the vast integrin family and its mechanism of activation and function.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hoard, Brock K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~